Faculty Opinions recommendation of Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

Author(s):  
Michael Singer
2021 ◽  
Vol 11 (7) ◽  
Author(s):  
Niyazi Acar ◽  
Bénédicte M. J. Merle ◽  
Soufiane Ajana ◽  
Zhiguo He ◽  
Stéphane Grégoire ◽  
...  

2015 ◽  
Vol 55 (2) ◽  
pp. 62-69 ◽  
Author(s):  
Eric H. Souied ◽  
Tariq Aslam ◽  
Alfredo Garcia-Layana ◽  
Frank G. Holz ◽  
Anita Leys ◽  
...  

2019 ◽  
Vol 30 (2) ◽  
pp. 376-381
Author(s):  
Alberto Piatti ◽  
Antonella Croce ◽  
Danilo Mazzacane ◽  
Giovanni Traina ◽  
Lina Ambrosino ◽  
...  

Purpose: To examine the effect of a long-term nutritional supplementation on age-related macular degeneration progression. Methods: In this prospective, double-blind, placebo-controlled study, 80 patients with intermediate age-related macular degeneration were randomized (2:1) to receive 1 tablet/day of a nutritional supplement containing a mixture of carotenoids, vitamins and omega-3 fatty acids or placebo. Age-related macular degeneration progression assessed by digital fundus photography (primary outcome) and best-corrected visual acuity were evaluated. Differences between arms were tested using chi-square test or Fisher’s exact test. Results: Seventy-four patients completed the follow-up at 24 months (48 in the treated arm and 26 in the placebo arm). An age-related macular degeneration progression was observed in the 2.1% of patients of the treated arm and in the 15.4% of patients in the placebo arm (p = 0.05, Fisher’s exact test). Best-corrected visual acuity data alone were not statistically significant among groups. Conclusion: A clinically meaningful stabilization of intermediate age-related macular degeneration over a period of 2 years may be obtained by treating patients with a mixture of carotenoids, vitamins and omega-3 fatty acids.


Sign in / Sign up

Export Citation Format

Share Document